Business Context and Reporting Period
Company: ORIC Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2026
Reporting Period: Fiscal quarter ended June 30, 2026
Event: Announcement of financial results for the quarter ended June 30, 2026, via press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. It only confirms that results for the quarter ended June 30, 2026, were announced.
Guidance, Outlook, and Risks
Management Commentary and Guidance: The text does not include specific guidance, outlook, or management commentary beyond the reference to the attached press release.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 3, 2026) for actual revenue, net income, and cash position figures.
- Verify the specific details of the fiscal quarter ended June 30, 2026, as the 8-K text only references the announcement.
- Check for any forward-looking statements or updated guidance contained within the attached press release.
- Confirm the company's liquidity status and cash runway, as these are critical for a pharmaceutical company and are not listed in the cover document.